TAKING STOCK
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Haemocell bounced 3p to 11.5p. As high as 36p a year ago, shares in the loss-making, USM-quoted blood filtration group have been off colour amid signs that sales were slipping. But Haemocell's directors are said to be baffled by the shares' recent weakness and are planning to bring forward the company's results, due on 17 December, to allay fears about current trading.
Shares in Emerald Energy gushed 0.25p higher to 2.5p. It plans to spend $3m drilling a 1.3 billion barrel oil target in Colombia to earn 60 per cent of an onshore field with
"massive potential". Emerald has now finalised arrangements to farm-in to the Apulo Block, containing the structure, which is currently 100 per cent held by Petroleos del Norte, part of Santo Domingo, Colombia's largest industrial group.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments